Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31044532 | 1.00 | GRM5 (0.47) | GRM5KCNH2CYP1A2FFAR1ALDH1A1 | |
| SCHEMBL31036128 | 0.84 | GRM5 (0.45) | GRM5KCNH2CYP1A2FFAR1ALDH1A1 | |
| SCHEMBL102810 | 0.84 | GRM5 (0.45) | GRM5KCNH2CYP1A2FFAR1ALDH1A1 | |
| SCHEMBL103774 | 0.81 | CYP1A2 (0.44) | GRM5KCNH2CYP1A2FFAR1ALDH1A1 | |
| Methyl Alcohol SCHEMBL28902013 | 0.80 | GRM5 (0.67) | GRM5KCNH2CYP1A2FFAR1ALDH1A1 | |
| SCHEMBL101818 | 0.80 | CYP1A2 (0.50) | GRM5KCNH2CYP1A2FFAR1ALDH1A1 | |
| SCHEMBL28489131 | 0.80 | FFAR1 (0.43) | GRM5FFAR1ERN1 | |
| SCHEMBL352291 | 0.79 | GRM5 (0.65) | GRM5KCNH2CYP1A2 | |
| SCHEMBL3907658 | 0.79 | GRM5 (0.47) | GRM5KCNH2CYP1A2FFAR1ALDH1A1 | |
| SCHEMBL1940910 | 0.79 | GRM5 (0.52) | GRM5KCNH2CYP1A2FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312348-B2 | RET inhibitors, pharmaceutical compositions and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2025-05-27 | — | — | US | disclosed |
| US-20220119382-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-04-21 | — | — | US | disclosed |
| US-20220119419-A1 | BYCYCLIC JAK INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2022-04-21 | — | — | US | disclosed |
| EP-3891149-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2021-10-13 | — | — | EP | disclosed |
| EP-3891148-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020198583-A1 | BICYCLIC JAK INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2020-10-01 | — | — | WO | disclosed |
| CN-111285874-A | RET inhibitors, pharmaceutical compositions thereof and uses thereof | 广东东阳光药业有限公司 | 2020-06-16 | — | — | CN | disclosed |
| CN-111285873-A | RET inhibitors, pharmaceutical compositions thereof and uses thereof | 广东东阳光药业有限公司 | 2020-06-16 | — | — | CN | disclosed |
| WO-2020114487-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020114494-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-06-11 | — | — | WO | disclosed |
| US-5217977-A | Lipoxygenase inhibitor for treating diseases medicated by leukotrienes | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-06-08 | — | — | US | disclosed |
| US-5202326-A | Inhibitor of enzyme 5-lipoxygenase; antiinflammatory and antiallergic agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-04-13 | — | — | US | disclosed |
| US-5196419-A | Lipoxygenase enzyme inhibitor | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-03-23 | — | — | US | disclosed |
| US-5134148-A | Heterocycles for use as inhibitors of leukotrienes | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-07-28 | — | — | US | disclosed |
| US-5134128-A | Immunosuppressive and antiproliferative activity for psoriasis and calcium homeostasis | ALLERGAN, INC. (US) | 1992-07-28 | — | — | US | disclosed |
| EP-0385679-A2 | Heterocyclic cyclic ethers with inhibitory activity on 5-lipoxygenase | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
| EP-0385662-A2 | Heterocycles with inhibitory activity of 5-lipoxygenase | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
| EP-0385663-A2 | Heterocyclic cycloalkanes as inhibitors of 5-lipoxygenase | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
| EP-0385680-A2 | Heterocyclic ethers as 5-lipoxygenase inhibitors | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
| EP-0372941-A2 | Anti-inflammatory 5-hydroxy-2-furanones | ALLERGAN, INC (US) | 1990-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119382-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | RET, SLC10A2, REL | GRM5 126/4885KCNH2 4602/4885CYP1A2 2437/4885 |
| US-20220119419-A1 | BYCYCLIC JAK INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | GRM5 2220/4885KCNH2 4188/4885CYP1A2 680/4885 |
| US-12312348-B2 | RET inhibitors, pharmaceutical compositions and uses thereof | RET, SLC10A2, REL | GRM5 126/4885KCNH2 4602/4885CYP1A2 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.